Ipca Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

12.91×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.76×	2.76×	2.50×	2.35×	2.87×
1.58×	1.58×	1.43×	1.30×	1.91×
1,071	1,071	931	767	1,581
4,067	4,067	3,583	3,180	3,383

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,926.20

Ipca Laboratories Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹48,868 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	12.91
Current Ratio	2.87	2.35	2.50	2.76	2.76
Quick Ratio	1.91	1.30	1.43	1.58	1.58
Cash, Equiv & ST Investments	1,581.2	767.3	930.6	1,070.5	1,070.5
Working Capital	3,383.5	3,179.9	3,582.8	4,066.7	4,066.7

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.